Metabolism and action of purine nucleoside analogs.
Recent investigations have identified many new purine nucleoside analogs that act as antimetabolites. This article focuses on the metabolism and mechanisms of action of tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2'-deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close to that stage. The diverse metabolic requirements for activation, unique mechanisms of action, and differential biological activities of these compounds are characterized and evaluated for prospective therapeutic application.
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
W
W
Plunkett
P P
PP
Saunders
D015762:2-Chloroadenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D017338:Cladribine; D003839:Deoxyadenosines / Q000494:pharmacology; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006151:Guanosine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D011684:Purine Nucleosides / Q000378:metabolism / Q000494:pharmacology*; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology; D014740:Vidarabine / Q000494:pharmacology
D003839:Deoxyadenosines; D011684:Purine Nucleosides; D006151:Guanosine; D015762:2-Chloroadenosine; D017338:Cladribine; D012254:Ribavirin; C010568:3-deazaguanosine; D006147:Guanine; C031096:neplanocin A; C010567:3-deazaguanine; D014740:Vidarabine; D000241:Adenosine; C033706:tiazofurin